Amendments to the Claims

This claim set replaces all previous claims in this application.

- 1. (Original) A pharmaceutical composition which comprises a pharmaceutically acceptable carrier or diluent and:
 - (a) an inhibitor of the RSV fusion protein; and
 - (b) a benzodiazepine derivative capable of inhibiting RSV replication.
- 2. (Currently amended) A composition according to claim 1, wherein component (b) is a compound of formula (V), or a pharmaceutically acceptable salt thereof,

wherein:

 R^1 represents C_{1-6} alkyl, aryl or heteroaryl;

 R^2 represents hydrogen or C_{1-6} alkyl;

each R^3 is the same or different and represents halogen, hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkylthio, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, amino, mono(C_{1-6} alkyl)amino, di(C_{1-6} alkyl)amino, nitro, cyano, - CO_2R ', -CONR'R'', -NH-CO-R', -S(O)R', - $S(O)_2R$ ', -NH- $S(O)_2R$ ', -S(O)NR'R" or - $S(O)_2NR$ 'R", wherein each R' and R" is the same or different and represents hydrogen or C_{1-6} alkyl;

n is from 0 to 3;

 R^4 represents hydrogen or C_{1-6} alkyl;

 $R^{5} \ represents \ C_{1-6} \ alkyl, \ aryl, \ heteroaryl, \ carbocyclyl, \ heterocyclyl, \ aryl-(C_{1-6} \ alkyl)-, \ heteroaryl-(C_{1-6} \ alkyl)-, \ heterocyclyl-(C_{1-6} \ alkyl)-, \ aryl-(C_{1-6} \ hydroxyalkyl)-, \ heterocyclyl-(C_{1-6} \ hydroxyalkyl)-, \ heterocyclyl-(C_{1-6} \ hydroxyalkyl)-, \ heterocyclyl-(C_{0}-C_{0})-, \ heterocyclyl-C_{0}-C_{0}-, \ heterocyclyl-C_{0}-C_{0}-, \ heterocyclyl-C_{0}-C_{0}-, \ heterocyclyl-C_{0}-, \ heterocycl$

X represents -CO-, -S(O)- or -S(O)₂-; and

 R^6 represents $C_{1\text{-}6}$ alkyl, hydroxy, $C_{1\text{-}6}$ alkoxy, $C_{1\text{-}6}$ alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl- $(C_{1\text{-}6}$ alkyl)-, heteroaryl- $(C_{1\text{-}6}$ alkyl)-, carbocyclyl- $(C_{1\text{-}6}$ alkyl)-, heterocyclyl- $(C_{1\text{-}6}$ alkyl)-O-, heteroaryl- $(C_{1\text{-}6}$ alkyl)-O-, carbocyclyl- $(C_{1\text{-}6}$ alkyl)-O-, heterocyclyl- $(C_{1\text{-}6}$ alkyl)-O- or -NR'R" wherein each R' and R" is the same or different and represents hydrogen, $C_{1\text{-}6}$ alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, aryl- $(C_{1\text{-}6}$ alkyl)-, heteroaryl- $(C_{1\text{-}6}$ alkyl)-, carbocyclyl- $(C_{1\text{-}6}$ alkyl)- or heterocyclyl- $(C_{1\text{-}6}$ alkyl)-.

3. (Original) A composition according to claim 2 wherein:

each R^3 is the same or different and represents halogen, hydroxy, $C_{1\text{-}6}$ alkyl, $C_{1\text{-}6}$ alkoxy, $C_{1\text{-}6}$ alkylthio, $C_{1\text{-}6}$ haloalkyl, $C_{1\text{-}6}$ haloalkoxy, amino, mono($C_{1\text{-}6}$ alkyl)amino, di($C_{1\text{-}6}$ alkyl)amino, nitro, cyano, - CO_2R ', -CONR'R", -NH-CO-R', -S(O)R', - $S(O)_2R$ ', -NH- $S(O)_2R$ ' or -S(O)NR'R", wherein each R' and R" is the same or different and represents hydrogen or $C_{1\text{-}6}$ alkyl;

R represents C_{1-6} alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl- $(C_{1-6}$ alkyl)-, heteroaryl- $(C_{1-6}$ alkyl)-, carbocyclyl- $(C_{1-6}$ alkyl)-, heterocyclyl- $(C_{1-6}$ alkyl)- or -XR⁶;

X represents -CO-, -S(O)- or -S(O) $_2$ -; and

 R^6 represents C_{1-6} alkyl, hydroxy, C_{1-6} alkoxy, C_{1-6} alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl- $(C_{1-6}$ alkyl)-, heteroaryl- $(C_{1-6}$ alkyl)-, carbocyclyl- $(C_{1-6}$ alkyl)- or -NR'R" wherein each R' and R" is the same or different and represents hydrogen, C_{1-6} alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, aryl- $(C_{1-6}$ alkyl)- or heteroaryl- $(C_{1-6}$ alkyl)-.

- 4. (Previously presented) A composition according to claim 2, wherein R^1 is C_{1-2} alkyl or aryl.
- 5. (Previously presented) A composition according to claim 2 wherein R² is hydrogen.
- 6. (Previously presented) A composition according to claim 2 wherein R^3 is halogen, hydroxy, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} alkylthio, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, amino, mono(C_{1-4} alkyl)amino or di(C_{1-4} alkyl)amino.

- 7. (Original) A composition according to claim 6, wherein R^3 is fluorine, chlorine, bromine, C_{1-2} alkyl, C_{1-2} alkoxy, C_{1-2} alkylthio, C_{1-2} haloalkyl, C_{1-2} haloalkoxy, amino, mono(C_{1-2} alkyl)amino or di (C_{1-2} alkyl)amino.
- 8. (Previously presented) A composition according to claim 2 wherein R^4 is hydrogen or C_{1-2} alkyl.
- 9. (Previously presented) A composition according to claim 2 wherein R^5 is C_{1-6} alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl- $(C_{1-4}$ alkyl)-, heteroaryl- $(C_{1-4}$ alkyl)-, carbocyclyl- $(C_{1-4}$ alkyl)-, heterocyclyl- $(C_{1-4}$ alkyl)-, aryl- $(C_{1-4}$ alkyl)-, heteroaryl- $(C_{1-4}$
- 10. (Original) A composition according to claim 9, wherein R^5 is C_{1-4} alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, phenyl- $(C_{1-2}$ alkyl)-, heteroaryl- $(C_{1-2}$ alkyl)-, phenyl- (C_0) -C(O)-, heteroaryl- (C_0) - (C_0) or -XR 6 .
- 11. (Original) A composition according to claim 10, wherein R^5 is C_{1-4} alkyl, phenyl, thienyl, furanyl, isoxazolyl, pyridyl, cyclopentyl, cyclohexyl, benzothienyl, dihydrobenzofuranyl, phenyl- CH_2 -, furanyl- CH_2 -, phenyl-C(O)-C(O)-, thienyl-C(O)-C(O)- or XR^6 .
- 12. (Previously presented) A composition according to claim 2 wherein, X is -CO- or - $S(O)_2$ -.
- 13. (Previously presented) A composition according to claim 2 wherein, when R^6 is a group NR'R" wherein each R' and R" is the same or different and represents hydrogen, C_{1-4} alkyl, aryl, carbocyclyl, heterocyclyl, aryl- $(C_{1-4}$ alkyl)- or heteroaryl- $(C_{1-4}$ alkyl)-.
- 14. (Original) A composition according to claim 13, wherein when R^6 is a group -NR'R'' each R' and R'' is the same or different and represents hydrogen, C_{1-4} alkyl, phenyl, thienyl, cyclohexyl, cyclopentyl or phenyl- CH_2 -.

- 15. (Original) A composition according to claim 14, wherein when R⁶ is a group –NR'R" and one of R' and R" is hydrogen.
- 16. (Previously presented) A composition according to claim 2 wherein R^6 is C_{1-6} alkyl, hydroxy, C_{1-6} alkoxy, C_{1-6} alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl- $(C_{1-4}$ alkyl)-, heteroaryl- $(C_{1-4}$ alkyl)-, carbocyclyl- $(C_{1-4}$ alkyl)-, heterocyclyl- $(C_{1-4}$ alkyl)-, heterocyclyl- $(C_{1-4}$ hydroxyalkyl)-, heterocyclyl- $(C_{1-4}$ hydroxyalkyl)-, carbocyclyl- $(C_{1-4}$ alkyl)-O-, heteroaryl- $(C_{1-4}$ alkyl)-O-, carbocyclyl- $(C_{1-4}$ alkyl)-O-, heterocyclyl- $(C_{1-4}$ alkyl)-O- or $-NR^*R^*$.
- 17. (Original) A composition according to claim 16, wherein R^6 is C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkylthio, aryl, heteroaryl, carbocyclyl, heterocycly, phenyl-(C_{1-2} alkyl)-, phenyl-(C_{1-2} alkyl)-, heteroaryl-(C_{1-2} alkyl)-, heteroaryl-(C_{1-2} hydroxyalkyl)- or -NR'R".
- 18. (Original) A composition according to claim 17, wherein R^6 is C_{1-4} alkyl, C_{1-4} alkoxy, phenyl, naphthyl, dihydrobenzofuranyl, benzodioxinyl, 9H-fluoren-9-onyl, indolyl, thienyl, furanyl, oxazolyl, isoxazolyl, pyrazolyl, pyridyl, benzothienyl, benzofuranyl, cyclopentyl, cyclohexyl, piperazinyl, piperidinyl, morpholinyl, phenyl- $(C_{1-2}$ alkyl)-, phenyl- $(C_{1-2}$ alkyl)-, phenyl- $(C_{1-2}$ alkyl)-O-, 1H-benzo[d]imidazol-2(3H)-onyl or -NR'R''.
- 19. (Currently amended) A composition according to claim 2 wherein the benzodiazepine derivative of formula (V) is a benzodiazepine derivative of formula

wherein:

R¹ is phenyl or methyl;

R³ is methyl or chlorine;

```
n is 0 or 1;

R<sup>4</sup> is hydrogen or methyl;

R<sup>5</sup> is phenyl-CH<sub>2</sub>-, furanyl-CH<sub>2</sub>-, thienyl-C(O)-C(O)- or -XR<sup>6</sup>;

X is -CO- or -S(O)<sub>2</sub>-; and
```

 R^6 is C_{1-4} alkyl, C_{1-4} alkoxy, phenyl, naphthyl, dihydrobenzofuranyl, benzodioxinyl, 9H-fluoren-9-onyl, indolyl, thienyl, furanyl, oxazolyl, isoxazolyl, pyrazolyl, pyridyl, benzothienyl, benzofuranyl, cyclopentyl, cyclohexyl, piperazinyl, piperidinyl, morpholinyl, phenyl- $(C_{1-2}$ alkyl)-, phenyl- $(C_{1-2}$ alkyl)-O-, lH-benzo[d]imidazol- (C_{1-4}) alkyl, onyl or -NR'R" wherein each R' and R" is the same or different and represents hydrogen, C_{1-4} alkyl, phenyl, thienyl, cyclohexyl, cyclopentyl or phenyl- (C_{1-2}) , the phenyl moiety in the group C_{1-2} alkyl, C_{1-2} alkoxy, C_{1-2} alkylthio, C_{1-2} haloalkyl or C_{1-2} haloalkoxy substituent;

the aryl moieties in the groups R^5 and R^6 being unsubstituted or substituted by 1, 2 or 3 substituents selected from fluorine, chlorine, bromine, iodine, C_{1-4} alkyl, C_{2-4} acyl, hydroxy, C_{1-4} alkoxy, C_{1-4} alkylthio, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, amino, mono(C_{1-4} alkyl)amino, di(C_{1-4} alkyl)amino, nitro, $-CO_2R'$, $-S(O)_2R'$ and $-S(O)_2NH_2$, wherein R' represents C_{1-2} alkyl;

the heteroaryl moieties in the groups R^5 and R^6 being unsubstituted or substituted by 1 or 2 substituents selected from fluorine, chlorine, bromine, C_{1-2} alkyl, C_{1-2} haloalkyl and di(C_{1-2} alkyl)amino; and

the heterocyclyl and carbocyclyl moieties in the R^6 group being unsubstituted or substituted by 1 or 2 substituents selected from fluorine, chlorine, bromine, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} haloalkyl and nitro.

20. (Original) A composition according to claim 1, wherein the benzodiazepine derivative of formula (V) is:

Cyclohexanecarboxylic acid 2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

- 3-Methoxy N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
- 4-Methoxy N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-benzamide;
- $2\text{-}Methoxy\ N\text{-}(2\text{-}oxo\text{-}5\text{-}phenyl\text{-}2\text{,}3\text{-}dihydro\text{-}lH\text{-}benzo[e][l,4]diazepin\text{-}3\text{-}yl)\text{-}benzamide;}$

N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-trifluoromethylbenzamide;

N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

Thiophene-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-3-amide;

Furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-amide;

Piperidine-1-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-amide;

Morpholine-4-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4] diazepin-3 -yl)-amide;

- 4-Nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
- 3-Nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
- 4-Methyl-piperazine-l-carboxylic acid-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-amide;
- $3,4-Dichloro-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-benzamide;\\ N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-2-trifluoromethyl-benzamide;\\ benzamide;$
 - 4-Bromo-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
 - 2-Methyl-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-benzamide;
 - 2-Chloro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
 - $2\text{-Nitro-N-}(2\text{-}oxo\text{-}5\text{-}phenyl\text{-}2,3\text{-}dihydro\text{-}lH\text{-}benzo[e][l,4]} diazepin\text{-}3\text{-}yl)\text{-}benzamide;$
- 2-Methoxy-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
- (S)-2-Methoxy-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-benzamide

Benzo[b]thiophene-3-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1 H-benzo[e] [1,4]diazepin-3-yl)-amide;

2,3-Dihydro-benzofuran-5-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

Isoxazole-5-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4] diazepin-3-yl)-amide;

Benzo[b]thiophene-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

Thiophen-3-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-amide;

N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-isonicotinamide;

N-(2-Oxo-5 -phenyl-2,3-dihydro-1 H-benzo [e][1,4] diazepin-3-yl)-nicotinamide;

N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-methanesulfonamide;

Propane-1-sulfonic acid-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-amide;

Butane-l-sulfonic acid-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-amide:

- 2-Bromo-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzenesulfonamide;
- 3-Bromo-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-benzenesulfonamide;
- 4-Bromo-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzenesulfonamide;
- 2-Fluoro-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-benzenesulfonamide;
 - 3-(2-Nitro-benzylamino)-5-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one;
 - $3-(3-Nitro-benzylamino)-5-phenyl-l, \\ 3-dihydro-benzo[e][l,4]diazepin-2-one;$
 - 3-(4-Nitro-benzylamino)-5-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one;
 - 3-(2-Methoxy-benzylamino)-5-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one;
 - 3-(3-Methoxy-benzylamino)-5-phenyl-l,3-dihydro-benzo[e][l,4]diazepin-2-one;
 - 5-Phenyl-3-(2-trifluoromethyl-benzylamino)-1,3-dihydro-benzo[e][1,4]diazepin-2-one;
 - 5-Phenyl-3-(3-trifluoromethyl-benzylamino)-1,3-dihydro-benzo[e][1,4]diazepin-2-one;
 - 5-Phenyl-3-(4-trifluoromethyl-benzylamino)-1,3-dihydro-benzo[e][l,4]diazepin-2-one;
 - $3\hbox{-}[(Furan-2\hbox{-}ylmethyl)\hbox{-}amino]\hbox{-}5\hbox{-}phenyl\hbox{-}1,}3\hbox{-}dihydro\hbox{-}benzo[e][1,4]diazepin-2\hbox{-}one;$
 - N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-acetamide;

 $N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-isobutyramide;\\ N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-methanesulfonamide;$

Furan-2-carboxylic acid (7-chloro-2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4] diazepin-3-yl)-amide;

Thiophene-2-carboxylic acid (7-chloro-2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e] [1,4]diazepin-3-yl)-amide;

Cyclohexanecarboxylic acid (7-Chloro-2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e] [1,4]diazepin-3-yl)-amide;

N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-methoxy-benzamide;

N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-4-methoxy-benzamide;

N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-2-nitro-benzamide;

2-(2-Methoxy-phenyl)N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3-yl)-acetamide;

2-(3-Methoxy-phenyl)N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3-yl)-acetamide;

2-(4-Methoxy-phenyl)N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3-yl)-acetamide;

 $2\hbox{-}(4\hbox{-Nitro-phenyl})N\hbox{-}(2\hbox{-}oxo\hbox{-}5\hbox{-phenyl-}2,3\hbox{-dihydro-}1H\hbox{-benzo[e][1,4]} diazepin-3\hbox{-yl})-acetamide;$

2-(3-Nitro-phenyl)N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-acetamide;

N-(2-Oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-2-(2-trifluoromethyl-phenyl)-acetamide;

N-(2-Oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-2-(3-trifluoromethyl-phenyl)-acetamide;

N-(2-Oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-2-(4-trifluoromethyl-phenyl)-acetamide;

- l-(2-Methoxy-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3-yl)-urea;
 - 1-(2-Nitro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-urea;
 - 1-(2-Chloro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-

urea;

- 1-(4-Chloro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl-urea;
- 1-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-p-tolyl-urea;
- 1-(2-Fluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-urea;
- 1-(4-Fluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4] diazepin-3-yl)-

urea;

- $(S)-l-(2-Fluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]\ diazepin-3-yl)-urea;$
- 4-Methanesulfonyl-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e] [1,4]diazepin-3-yl)-benzamide;
- (S)-4-Methanesulfonyl-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
- 5-Acetyl-2-ethoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
- (S)-5-Acetyl-2-ethoxy-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3-yl)-benzamide;
- 6-Fluoro-4H-benzo[1,3]dioxine-8-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;
- (S)-6-Fluoro-4H-benzo[1,3]dioxine-8-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;
- (S) 2 Methoxy N (2 oxo 5 phenyl 2, 3 dihydro 1H benzo[e][1,4] diazepin 3 yl) 4 trifluoromethyl benzamide;
- 2,4,5-Trifluoro-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-benzamide;
- (S)-2,4,5-Trifluoro-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-benzamide;
 - 2-Hydroxy-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-benzamide;

- (S)-2-Hydroxy-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-benzamide;
- 1H-Indole-7-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4] diazepin-3-yl)-amide;
- (S)-1H-Indole-7-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-amide;
- 3-Methoxy-naphthalene-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;
- (S)-3-Methoxy-naphthalene-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;
- N-[7-Chloro-5-(2-fluoro-phenyl)-2-oxo-2,3-dihydro-lH-benzo[e][1,4]diazepine-3-yl]-4-methoxoy-benzamide;
- 1-(2-Fluoro-benzyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;
- 1-(4-Methoxy-benzyl)-3-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4] diazepin-3-yl)-urea;
- 1-(3-Methyl-benzyl)-3-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-urea;
- l-(2-Oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-3-(4-trifluoromethyl-phenyl)-urea;
- 4-Chloro-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
- 4-Methoxy-3-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide;
- 3-Methoxy-2-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-benzamide;
- 5-Chloro-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)benzamide;
- 5-Fluoro-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-benzamide;

- 2-Methoxy-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-benzamide;
- 5-Methoxy-2-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-benzamide;
- 3-Methoxy-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-benzamide;
- 3-(2-Methoxy-phenyl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)propionamide;
- 3-(3-Methoxy-phenyl)-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-propionamide;
- 3-(4-Methoxy-phenyl)-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-propionamide;
- N-[5-(3-Chloro-phenyl)-2-oxo-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl]-2-methoxy-benzamide;
- N-[5-(3-Chloro-phenyl)-2-oxo-5-phenyl-2, 3-dihydro-lH-benzo[e][1,4] diazepin-3-yl]-4-methoxy-benzamide;
- N-[5-(3-Chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl]-2-nitro-benzamide;
- N-[5-(3-Chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl]-4-nitro-benzamide;
- 4-Methoxy-N-[2-oxo-5-(4-trifluoromethyl-phenyl)-2,3-dihydro-lH-benzo[e] [1,4]diazepin-3-yl]-benzamide;
- 2-Methoxy-N-[2-oxo-5-(3-trifluoromethyl-phenyl)-2,3-dihydro-lH-benzo[e] [1,4]diazepin-3-yl]-benzamide;
- 4-Methoxy-N-[2-oxo-5-(3-trifluoromethyl-phenyl)-2,3-dihydro-lH-benzo[e] [1,4]diazepin-3-yl]-benzamide;
 - 2-Ethoxy-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4] diazepin-3-yl)-benzamide;
- 2,4-Dimethoxy-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-benzamide;
- 2-Bromo-5-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-benzamide;

- 2-Methoxy-N-[5-(3-mehtoxy-phenyl)-2-oxo-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl]-benzamide
- N-[5-(3-Methoxy-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-4-nitro-benzamide;
- 2-Methoxy-N-(8-methyl-2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-benzamide;
- 2-Chloro-4-methanesulfonyl-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-benzamide;
- 2-Dimethylamino-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-benzamide;
- (2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-carbamic acid benzyl ester;
- l-(3,5-Dimethyl-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3-yl)-urea;
- $\label{lem:condition} \hbox{1-(2-Oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-3-(4-trifluoromethoxy-phenyl)-urea;}$
- 1-(4-Bromo-2-trifluoromethyl-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;
- l-(4-Bromo-benzyl)-3-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-urea; l-(2,3-Dichloro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-urea;
- 1-(2,6-Dimethyl-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-urea;
- l-(2-Chloro-6-methyl-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-urea;
- 1-(4-Nitro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea; l-(2-Methylsulfanyl-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;
- $l-(2,6-Dichloro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]\ diazepin-3-yl)-urea;$

- 5-tert-Butyl-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-benzamide;
- 2,5-Dimethoxy-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-benzamide;
- 1 -(2,6-Difluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-urea;
- l-(3-Fluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-urea; l-(3-Methoxy-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3-yl)-urea;
- l-(2-Oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-3-(3-trifluoromethyl-phenyl)-urea;
 - 1-(3-Chloro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e]1,4] diazepin-S-yl)-urea;
- 2-Methoxy-4-methylsulfanyl-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-benzamide;
- 4-Methanesulfonyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
- N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)terephthalamic acid methyl ester;
 - 2-Fluoro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
 - 2,6-Difluoro-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-benzamide;
 - N-(2-Oxo-5-phenyl-2, 3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-propoxy-benzamide;
 - 2-Iodo-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
- 3-Methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-terephthalamic acid methyl ester;
- 4-Amino-5-chloro-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e] [1,4]diazepin-3-yl)-benzamide;
 - $1\hbox{-}(2\hbox{-}Oxo\hbox{-}5\hbox{-}phenyl\hbox{-}2,3\hbox{-}dihydro\hbox{-}lH\hbox{-}benzo[e][l,4]diazepin\hbox{-}3\hbox{-}yl)\hbox{-}3\hbox{-}m\hbox{-}tolyl\hbox{-}urea;}$
- 2-Methylsulfanyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
- 2-Methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-5-sulfamoyl-benzamide;

- 2-Hydroxy-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-3-phenyl-propionamide
- 3-Hydroxy-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-3-phenyl-propionamide;
- $3\hbox{-}(2\hbox{-Fluoro-phenyl})\hbox{-l-methyl-}1\hbox{-}(2\hbox{-}oxo\hbox{-}5\hbox{-phenyl-}2,3\hbox{-dihydro-}1H\hbox{-benzo[e][1,4]diazepin-}3\hbox{-yl})\hbox{-urea};$
- 2-Methoxy-N-methyl-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
 - 1-tert-Butyl-3-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-urea;
 - 1-Cycloheyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;
 - 1-Ethyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;
 - 1-Butyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;
- 4,5-Dimethyl-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e] [1,4]diazepin-3-yl)amide;
- Piperidine-1-carboxylic acid (7-chloro-2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e] [1,4]diazepin-3-yl)-amide;
- N-[5-(3-Chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)acetamide;
- N-[5-(3-Chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl]-isobutyramide;
- Furan-2-carboxylic acid [5-(3-chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-amide;
- Thiophene-2-carboxylic acid [5-(3-chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl]-amide;
- Cyclohexanecarboxylic acid [5-(3chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl]-amide;
- Piperidine-1-carboxylic acid [5-(3-chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl]-amide;
- N-[5-(3-Chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl]isonicotinamide;

5-Methyl-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e] [1,4] diazepin-3-yl)-amide;

Pyrazine-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3-yl)-amide;

N-[5-(3-Methoxy-phenyl)-2-oxo-5-phenyl2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl]-isobutyramide;

Thiophene-2-carboxylic acid [5-(3-methoxy-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl] -amide;

Cyclohexanecarboxylic acid [5-(3-methoxy-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-amide;

Piperidine-1-carboxylic acid [5-(3-methoxy-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-amide;

Piperidine-4-carboxylic acid [5-(3-methoxy-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1 H-benzo[e][1,4]diazepin-3-yl]-amide;

Cyclohexanecarboxylic acid (8-chloro-2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e] [1,4]diazepin-3-yl)-amide;

Thiophene-2-carboxylic acid (8-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

1-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-thiophene-2-yl-urea;

 $1\hbox{-}(2\hbox{-}Oxo\hbox{-}5\hbox{-}phenyl\hbox{-}2,3\hbox{-}dihydro\hbox{-}1H\hbox{-}benzo[e][1,4]diazepin\hbox{-}3\hbox{-}yl)\hbox{-}3\hbox{-}thiophene\hbox{-}3\hbox{-}yl\hbox{-}urea;}$

Pyridine-2 -carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4] diazepin-3-yl)-amide;

1H-Pyrazole-4-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-l H-benzo[e] [1 ,4] diazepin-3-yl)-amide;

6-Dimethylamino-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-nicotinamide;

2-Ethoxy-naphthalene-l -carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-amide;

9-Oxo-9H-fluorene-l -carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e] [1,4]diazepin-3-yl)-amide;

2-Oxo-2,3-dihydro-benzoimidazole-l -carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

- (2-Oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)carbamic acid tert-butyl ester;
- (S)-4,5-Dibromo-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-amide;
- (S)-Benzofuran-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e] [1,4]diazepin-3-yl)-amide;
 - (2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-carbamic acid methyl ester;
 - (2-Oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-carbamic acid ethyl ester;
- (2-Oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-carbamic acid isobutyl ester; and
- 2-Oxo-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-thiophene-2-yl-acetamide.
- 21. (Previously presented) A composition according to claim 2, wherein the benzodiazepine derivative of formula (V) is l-(2-fluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-urea, 2-methoxy-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-benzamide or 4-methanesulfonyl-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide.
- 22. (Original) A composition according to claim 21, wherein the benzodiazepine derivative of formula (V) is 1-(2-fluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3-yl)-urea.
- 23. (Currently amended) A composition according to claim 1, wherein component (a) is a compound of formula (I), or a pharmaceutically acceptable salt thereof,

$$\begin{array}{c|c} R_2 & N & Q \\ \hline R_1 & N & X \\ & X & Y \end{array} \hspace{-0.5cm} (I)$$

wherein:

X is a direct link or C_{1-6} alkyl; said C_{1-6} alkyl being optionally substituted with halogen, oxo, cyano, hydroxyl, OCOR₄ or $S(O)_n$ - C_{1-6} alkyl;

Y is R_4 , NR_4R_5 , $NCOR_4$, $=N-OR_4$, $-CONHR_4$, $COOR_4$, $-OR_4$, aryl, heteroaryl, cyclyl or heterocyclyl, where R_4 and R_5 are H or C_{1-6} alkyl;

Z is CR_6R ', where R_6 and R' are independently H, or straight, branched or cyclic C_{1-6} alkyl;

n is 1-2;

 R_1 is <u>H</u>, CONR₄R₅, CO₂R₄ or C₁₋₆ alkyl, said C₁₋₆ alkyl can be optionally substituted with OR₄ or NR₈R₉;

R₈ and R₉ are each independently H, C₁₋₆ alkyl, SO₂R₅, CO₂R₄ or COR₄;

 R_2 is selected from the group consisting of \underline{H} , NH_2 , $CONR_6R$, heteroaryl, C_{2-6} alkenyl, CO_2R_4 , $N=CPh_2$, $C(=NH)NH_2$ and C_{1-6} alkyl; said alkyl optionally substituted with a member selected from the group consisting of halogen, CN, $NR_{10}R_{11}$, OSO_2R_4 and OR_4 ;

 R_{10} and R_{11} are each independently selected from the group consisting of H, C_{1-6} alkyl, C_{3-6} cycloalkyl, CO_2R_4 , COR_4 and SO_2R_4 ;

 R_3 is selected from the group consisting of (1) CO_2R_9 ; (2) C_{1-6} alkyl optionally substituted with CN, OR_4 or NR_6R' ; (3) H; and (3)-(4) C_{2-6} alkenyl substituted with CN;

Q is a member selected from the group consisting of

A is C or N, optionally substituted with H, halogen, C_{1-6} alkyl, C_{2-6} alkenyl, cyano- C_{1-6} alkyl, CO_2R_4 , aryl, benzoaminocarbonyl, hydroxybenzyl, $SO_2NR_4R_5$ or C_{3-6} cycloalkyl. Where A is carbon, it may also be optionally substituted by O or S via a double bond;

B is C or N; where B is C it may be optionally substituted by H, C_{1-6} alkyl, NO_2 , CN, halogen, COR_4 , $COOR_4$, $CONHR_4C(=NH)NH_2$ or $C(=N0H)NH_2$.

24. (Previously presented) A composition according to claim 23, wherein at least two of R_1 , R_2 and R_3 are hydrogen, and the other is hydrogen or $-C(NH)-NH_2$ and/or either -X-Y is H, or X

is a C_1 - C_6 alkylene group which is unsubstituted or substituted by a hydroxy group and Y is H, OH, CN, -NR'R", -COR', -SO₂R' or phenyl, wherein R' and R" are the same or different and represent a C_1 - C_4 alkyl group and/or Z is -CH₂- and/or Q is a moiety

wherein B is -CH- or -N-, A_1 is -C(O)- or -NH- and A_2 is -CH₂-, -CHR'- or -NR"-, wherein R' is a halogen atom and R" represents a hydrogen atom or a C_{1-4} alkyl, C_{2-4} alkenyl, C_{3-6} cycloalkyl, -SO₂-(C_{1-6} alkyl), -SO₂-N(C_{1-6} alkyl)₂ or -(CO-NH)_a-(C_{1-4} alkyl)-phenyl group, wherein a is 0 or 1, which group is unsubstituted or is substituted with a hydroxy or cyano substituent.

25. (Previously presented) A composition according to claim 1, wherein component (a) is a compound of the formula (II), or a pharmaceutically acceptable salt thereof

$$Z-Y \xrightarrow{L_2} X \xrightarrow{(R_1)_n} X$$

$$Z-Y \xrightarrow{R_3} (II)$$

wherein:

L₁ is -CH₂- or -CHR₂-CO-

each X is the same or different and is CH or N;

each R_1 is the same or different and is $C_{1\text{-}6}$ alkyl, halogen, hydroxy, phenyl or $(CH_2)_m$ =NH₂;

n is 1 or 2;

R2 is C_{1-6} alkoxy or C_{1-6} alkoxy-phenyl;

R3 is C_{1-6} alkyl;

L2 is $-CH_2$ - or -NH-;

Y is C_{1-6} alkyl or C_{1-6} alkenyl;

Z is H, $N(R_4)2$ -, $-C(=O)-R_5$, $-C(=CH_2)-R_5$, $-CH(OH)-R_5$, $-CH(CH_3)-R_5$, $-CH(OCH_3)-R_5$; each R_4 is the same or different and is H, C1-6 alkyl.

 R_5 is $C_{1\text{-}6}$ alkyl-carbonyl, amino, hydroxyl, aryl, heteroaryl, carbocyclyl, heterocyclyl; and m=1-6

26. (Previously presented) A composition according to claim 1, wherein component (a) is: 1-Cyclopropyl-3-[1-(4-hydroxy-butyl)-lH-benzoimidazol-2-ylmethyl]-l,3-dihydroimidazo[4, 5-c]pyridin-2-one

 $\label{lem:continuous} $\{2-[2-(1,2-Dihydro-benzotriazol-l-ylmethyl)-benzoimidazol-l-yl]] ethyl}-diethyl-amine $\{2-[2-(3-Iodo-2,3-dihydro-indazol-l-ylmethyl)-benzimidazol-l-yl]-ethyl}-dimethyl-amine $\{2-[2-(3-Iodo-2,3-dihydro-indazol-l-ylmethyl)-benzimidazol-l-yl]-ethyl}.$

1-Isopropenyl-3-[1-(3-methyl-butyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydrobenzoimidazol-2-one

1-(4-Hydroxy-benzyl)-3-[1-(3-methyl-butyl)-lH-benzoimidazol-2-ylmethyl]-1,3-dihydrobenzoimidazol-2-one

l-Ethyl-3-[l-(4-hydroxy-butyl)-lH-benzoimidazol-2-ylmethyl]-l,3-dihydrobenzoimidazol-2-one

 $\label{thm:continuous} 7\mbox{-}[2\mbox{-}(3\mbox{-}Isopropenyl\mbox{-}2\mbox{-}oxo\mbox{-}2\mbox{,}3\mbox{-}dihydrobenzoimidazol\mbox{-}l\mbox{-}ylmethyl)\mbox{-}benzoimidazol\mbox{-}l\mbox{-}yll\mbox{-}heptanenitril$

 $5-\{3-[1-(3-Methane sulfonyl-propyl)-lH-benzoimidazol-2-ylmethyl]-2-oxo-2, 3-dihydrobenzoimidazol-1-yl\}-pentanenitrile$

3-[1-(3-Methyl-buty)-lH-benzoimidazol-2-ylmethyl]-2-oxo-2,3-dihydro-benzoimidazol-1-carboxylic acid benzylamide

1-Methanesulfonyl-3-[1-(3-methyl-butyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydrobenzoimidazol-2-one

3-[1-(3-Methyl-butyl)-1H-benzoimidazol-2-ylmethyl]-2-oxo-2,3-dihydro-benzoimidazol-1-sulfonic acid dimethylamide

l-Isopropenyl-3-(l-propyl-lH-benzoimidazol-2-ylmethyl)-1,3-dihydro-imidazo[4,5-c]pyridine-2-one

Bis(5-amidino-2-benzimidazolyl)-methane

2-{2-[1-[1-(2-Amino-ethyl)-piperidin-4-ylamino]-4-methyl-benzoimidazol-1-ylmethyl}-6-methyl-pyridin-3-ol

or a pharmaceutically acceptable salt thereof.

- 27. (Previously presented) A composition according to claim 1, wherein component (a) is 1-cyclopropyl-3-[1-(4-hydroxy-butyl)-1H-benzoimidazol-2-ylmethyl]-1 ,3-dihydro-imidazo[4,5-c]pyridin-2-one, {2-[2-(1,2-dihydro-benzotriazol-1-ylmethyl)-benzoimidazol-1-yl]] ethyl}-diethyl-amine, {2-[2-(3-iodo-2,3-dihydro-indazol-1-ylmethyl)-benzimidazol-1-yl]-ethyl}-dimethyl-amine or a pharmaceutically acceptable salt thereof.
- 28. (Previously presented) A composition according to claim 1, wherein component (a) is 1-cyclopropyl-3-[1-(4-hydroxy-butyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydro-imidazo[4,5-c]pyridin-2-one or 1-Isopropenyl-3-(1-propyl-1H-benzoimidazol-2-ylmethyl)-1,3-dihydro-imidazo[4,5-c]pyridine-2-one or a pharmaceutically acceptable salt thereof.
- 29. (Previously presented) A composition according to claim 1, wherein component (a) is present in an amount of from 0.025 wt% to 10 wt%.
- 30. (Previously presented) A composition according to claim 1, wherein component (b) is present in an amount of 0.025 wt% to 10 wt%.
- 31. (Previously presented) A composition according to claim 1, for use in the treatment of the human or animal body.
- 32. (Previously presented) The use of:
 - (a) an RSV fusion protein inhibitor as defined in claim 1; and
- (b) a benzodiazepine derivative defined in claim 1, in the manufacture of a medicament for use in treating or preventing an RSV infection.

- 33. (Previously presented) The use according to claim 32, wherein component (a) is present in an amount of from 0.025 wt% to 10 wt% and component (b) is present in an amount of 0.025 wt% to 10 wt%.
- 34. (Previously presented) A product comprising:
 - (a) an RSV fusion protein inhibitor as defined in claim 1; and
- (b) a benzodiazepine derivative as defined claim 1; for separate, simultaneous or sequential use in the treatment of the human or animal body.
- 35. (Original) A product according to claim 34 for separate, simultaneous or sequential use in treating or preventing an RSV infection.
- 36. (Previously presented) A method of treating or preventing an RSV infection in a patient, which method comprises the administration to said patient of:
 - (a) an RSV fusion protein inhibitor as defined in claim 1; and
 - (b) a benzodiazepine derivative as defined in claim 1.
- 37. (Previously presented) The use of an RSV fusion protein inhibitor as defined in claim 1, in the manufacture of a medicament for use in treating or preventing an RSV infection, by co-administration with a benzodiazepine derivative as defined in claim 1.
- 38. (Previously presented) The use of a benzodiazepine derivative as defined in claim 1, in the manufacture of a medicament for use in treating or preventing an RSV infection, by coadministration with an RSV fusion protein inhibitor as defined in claim 1.